Bio-Rad Laboratories Inc. (BUW/BIO) has faced notable stock fluctuations, registering a 47% fall over five years and 61% drop in three years. NYSE:BIO and BIO.B experienced increased valuation challenges following Q3 losses and a miss of second-quarter 2025 forecasts. Despite the pressures, Bio-Rad managed to exceed Q2 2025 earnings estimates, leading to boosted outlooks. However, Q3 earnings fell short of estimates despite surpassing revenues, causing stocks to drop. The launch of new
StarBright Dye and
droplet digital PCR systems showcased an innovative approach, bolstering molecular testing reach.
Franklin Resources and
Swiss National Bank adjusted their stakes in BIO, with the former buying shares and the latter lowering its position. There were reports of
executive stock sales despite institutional investor favoritism towards BIO. In
partnership news, an expansion with Biodesix offered more cancer diagnostic solutions while the acquisition of Stilla Technologies fortified Bio-Rad's digital PCR solutions. Bio-Rad also mourned the loss of Co-Founder Alice Schwartz. Despite several valuation concerns and macroeconomic uncertainties, analysts have deemed Bio-Rad an investment bet and some, a 'classic stock', raising price targets.
Bio-Rad Laboratories Stocks News Analytics from Wed, 12 Oct 2022 07:00:00 GMT to Fri, 05 Dec 2025 08:13:14 GMT -
Rating -3
- Innovation 5
- Information 7
- Rumor -2
